FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine.
The Advisory Committee on Immunization Practices (ACIP) the Committee on Infectious Diseases, American Academy of Pediatrics; and the American Academy of Family Physicians recommend that all infants receive Haemophilus influenzae type b (Hib) conjugate vaccine and hepatitis B vaccine. On October 2, 1996, the Food and Drug Administration (FDA) licensed a combined Hib conjugate and hepatitis B (recombinant) vaccine (COMVAX) for infants. Since 1991, the antigenic components of COMVAX have been used routinely in separate vaccines and have contributed to the declining incidence of infant Hib disease and hepatitis B virus (HBV) infection in the United States.
D017277:Drug Approval; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D007223:Infant; D014481:United States; D014486:United States Food and Drug Administration; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology
C104289:COMVAX; D018073:Haemophilus Vaccines; D017325:Hepatitis B Vaccines; D018074:Vaccines, Conjugate